Northern Trust Corp Buys 308,886 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Northern Trust Corp boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 17.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,038,202 shares of the company's stock after purchasing an additional 308,886 shares during the period. Northern Trust Corp owned about 0.93% of Hims & Hers Health worth $49,284,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. SlateStone Wealth LLC boosted its stake in shares of Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock worth $257,000 after acquiring an additional 413 shares in the last quarter. Blume Capital Management Inc. boosted its position in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the period. Summit Investment Advisors Inc. grew its holdings in Hims & Hers Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock valued at $480,000 after purchasing an additional 628 shares during the last quarter. Harbour Investments Inc. raised its position in shares of Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after purchasing an additional 833 shares during the period. Finally, Stonekeep Investments LLC lifted its stake in shares of Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company's stock worth $410,000 after buying an additional 882 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the transaction, the chief executive officer now directly owns 97,687 shares of the company's stock, valued at $5,692,221.49. The trade was a 56.74 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now directly owns 157,345 shares of the company's stock, valued at $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 650,500 shares of company stock valued at $25,790,311. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded up $0.64 during trading on Friday, hitting $52.04. 61,754,901 shares of the company's stock traded hands, compared to its average volume of 18,273,157. The company has a market cap of $11.56 billion, a PE ratio of 118.28 and a beta of 1.84. The firm's fifty day moving average price is $32.74 and its 200 day moving average price is $32.16. Hims & Hers Health, Inc. has a twelve month low of $12.07 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same period in the previous year, the business earned $0.05 earnings per share. The company's quarterly revenue was up 110.7% on a year-over-year basis. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HIMS. UBS Group reiterated a "mixed" rating on shares of Hims & Hers Health in a research note on Tuesday. Citigroup reaffirmed a "sell" rating and issued a $30.00 price target (up from $25.00) on shares of Hims & Hers Health in a research report on Tuesday. Needham & Company LLC reissued a "buy" rating and set a $61.00 price objective on shares of Hims & Hers Health in a research report on Tuesday. Piper Sandler reaffirmed a "neutral" rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday. Finally, Canaccord Genuity Group upped their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health currently has an average rating of "Hold" and a consensus price target of $37.67.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.